Your browser doesn't support javascript.
loading
Effects, Doses, and Applicability of Gestrinone in Estrogen-Dependent Conditions and Post-Menopausal Women.
Renke, Guilherme; Antunes, Mariana; Sakata, Renato; Tostes, Francisco.
Afiliação
  • Renke G; Nutrindo Ideais Performance and Nutrition Research Center, Rio de Janeiro 22411-040, Brazil.
  • Antunes M; Nutrindo Ideais Performance and Nutrition Research Center, Rio de Janeiro 22411-040, Brazil.
  • Sakata R; Nutrindo Ideais Performance and Nutrition Research Center, Rio de Janeiro 22411-040, Brazil.
  • Tostes F; Nutrindo Ideais Performance and Nutrition Research Center, Rio de Janeiro 22411-040, Brazil.
Pharmaceuticals (Basel) ; 17(9)2024 Sep 22.
Article em En | MEDLINE | ID: mdl-39338410
ABSTRACT
Gestrinone (R-2323), or ethylnorgestrienone, is a synthetic steroid of the 19-nortestosterone group more commonly used as an oral, intravaginal, or subcutaneous implant for the treatment of endometriosis, contraception, and estrogen-dependent conditions such as hypermenorrhea, premenstrual dysphoria, and intense menstrual cramps. This review aims to reevaluate the routes, doses, and applicability proposed for using gestrinone, including its use in new conditions such as menopause, lipedema, and sarcopenia. Here, we present the possible application of gestrinone as a long-acting therapeutic possibility through hormonal implants and the benefits and potential risks. Available evidence on the safety of doses and routes is limited. Gestrinone appears to be effective compared to other progestins and may have some advantages in the treatment of estrogen-dependent pathologies. Future research must evaluate gestrinone's long-term safety and potential therapeutic indications.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Brasil País de publicação: Suíça